TriSalus Life Sciences, Inc.
TriSalus Life Sciences, Inc.（TLSI）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · TLSI · 截至 2026年6月8日
活动摘要
买入笔数
6
P-Purchase only
卖出笔数
14
近12个月
买卖比
0.43
Buy/Sell (by trades)
整体情绪
TriSalus Life Sciences, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
TLSI 季度内部人买卖趋势
TLSI 内幕交易卖出 · TLSI 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · TLSI CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
TLSI 高管卖出股份 · TLSI 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| May 15, 2026 | Marshak Richard Chief Commercial Officer | Sale | 543 | $1K | Form 4 |
| May 15, 2026 | Wahlstrom Mats Director | Purchase | 60,000 | $152K | Form 4 |
| May 15, 2026 | Stansky Michael P Director | Purchase | 410,000 | $1.02M⚡ | Form 4 |
| May 15, 2026 | Stansky Michael P Director | Purchase | 200,000 | $500K | Form 4 |
| May 15, 2026 | Szela Mary T CEO and President · Director | Purchase | 39,682 | $103K | Form 4 |
| May 15, 2026 | Patience David CFO | Purchase | 7,100 | $17K | Form 4 |
| May 15, 2026 | Gordon Gary B. Director | Purchase | 10,000 | $25K | Form 4 |
| May 14, 2026 | HICKS KERRY R Director | Award | 28,201 | — | Form 4 |
| May 14, 2026 | Wahlstrom Mats Director | Award | 34,226 | — | Form 4 |
| May 14, 2026 | Wahlstrom Mats Director | Award | 37,602 | — | Form 4 |
| May 14, 2026 | Gordon Gary B. Director | Award | 24,553 | — | Form 4 |
| May 14, 2026 | Gordon Gary B. Director | Award | 28,201 | — | Form 4 |
| May 14, 2026 | MATLIN DAVID J Director | Award | 23,065 | — | Form 4 |
| May 14, 2026 | MATLIN DAVID J Director | Award | 28,201 | — | Form 4 |
| May 14, 2026 | Valle William Director | Award | 24,553 | — | Form 4 |
| May 14, 2026 | Valle William Director | Award | 28,201 | — | Form 4 |
| May 14, 2026 | Stansky Michael P Director | Award | 20,089 | — | Form 4 |
| May 14, 2026 | Stansky Michael P Director | Award | 23,501 | — | Form 4 |
| Jul 31, 2025 | Frankenius Equity AB 10 percent owner | Other | 759,000 | — | Form 4 |
| Jul 31, 2025 | MATLIN DAVID J Director | Other | 330,000 | — | Form 4 |
| Mar 11, 2026 | Devlin Jodi Chief of Clinical Operations | Sale | 1,162 | $5K | Form 4 |
| Mar 12, 2026 | Devlin Jodi Chief of Clinical Operations | Sale | 1,772 | $7K | Form 4 |
| Mar 16, 2026 | Devlin Jodi Chief of Clinical Operations | Sale | 273 | $1K | Form 4 |
| Mar 11, 2026 | Cox Bryan F. Chief of Research | Sale | 1,138 | $5K | Form 4 |
| Mar 12, 2026 | Cox Bryan F. Chief of Research | Sale | 1,467 | $6K | Form 4 |
Szela Mary T
CEO and President · Director
日期
May 15
股数
39,682
均价
$2.59
总金额
$103K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 TLSI 内幕交易
TLSI 内幕交易
TriSalus Life Sciences, Inc.（TLSI）内幕交易数据来源于公司内部人（包括Stansky Michael P (Director), Szela Mary T (CEO and President · Director), Marshak Richard (Chief Commercial Officer)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。TLSI内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看TriSalus Life Sciences, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
TLSI 内幕交易 · 5个问题TriSalus Life Sciences, Inc.（TLSI）的内部人包括高管和董事，如Stansky Michael P (Director), Szela Mary T (CEO and President · Director), Marshak Richard (Chief Commercial Officer)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026